EHA 2021 | MANIFEST: ruxolitinib plus pelabresib for JAK-inhibitor naïve myelofibrosis
Marina Kremyanskaya
• 15 Jun 2021
Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, talks on the findings of a subgroup analysis of Arm 3 of the Phase II MANIFEST study (NCT02158858), investigating pelabresib in combination with ruxolitinib for patients with myelofibrosis who are JAK inhibitor-naïve. Pelabresib is a first-in-class, oral, small-molecule BET inhibitor. Dr Kremyanskaya reports that at 24 weeks, 67% of patients achieve a 35% reduction in spleen volume, with a median reduction of 50%. Pelabresib was generally well-tolerated. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Marina Kremyanskaya, MD, PhD, has participated in a consultancy role for Protagonist Therapeutics.
